Related references
Note: Only part of the references are listed.Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book
Raul D. Santos et al.
EUROPEAN HEART JOURNAL (2023)
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Yajnavalka Banerjee et al.
EXPERT OPINION ON DRUG SAFETY (2022)
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2022)
Inclisiran: How Widely and When Should We Use It?
Angela Pirillo et al.
CURRENT ATHEROSCLEROSIS REPORTS (2022)
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
The growth of siRNA-based therapeutics: Updated clinical studies
M. May Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Inclisiran in lipid management: A Literature overview and future perspectives
Pietro Scicchitano et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Engineering precision nanoparticles for drug delivery
Michael J. Mitchell et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Ionizable lipid nanoparticles for in utero mRNA delivery
Rachel S. Riley et al.
SCIENCE ADVANCES (2021)
Self-assembled mRNA vaccines
Jeonghwan Kim et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?
Aditi Mehta et al.
ADVANCED HEALTHCARE MATERIALS (2021)
Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins
Yaxian Zhou et al.
ACS CENTRAL SCIENCE (2021)
Rare versus common diseases: a false dichotomy in precision medicine
Brian Hon Yin Chung et al.
NPJ GENOMIC MEDICINE (2021)
Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles
Michele Schlich et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2021)
A Critical Review of the Efficacy and Safety of Inclisiran
Jennifer Hardy et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2021)
The Limitless Future of RNA Therapeutics
Tulsi Ram Damase et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement
Rumiana Tenchov et al.
ACS NANO (2021)
A Comprehensive Review on the Applications of Exosomes and Liposomes in Regenerative Medicine and Tissue Engineering
Mojtaba Shafiei et al.
POLYMERS (2021)
Lipid nanoparticles for mRNA delivery
Xucheng Hou et al.
NATURE REVIEWS MATERIALS (2021)
Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol
Pooria Nakhaei et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Nanoplatforms for mRNA Therapeutics
Chaoyang Meng et al.
ADVANCED THERAPEUTICS (2021)
Inclisiran-New hope in the management of lipid disorders?
Krzysztof Dyrbus et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Reverse Transcription Quantitative Polymerase Chain Reaction Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNA Interference Therapeutics
Elena Castellanos-Rizaldos et al.
NUCLEIC ACID THERAPEUTICS (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Statins and PCSK9 inhibitors: A new lipid-lowering therapy
Enrique Gallego-Colon et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions fromthe ORION trials
Arjen J. Cupido et al.
CARDIOVASCULAR RESEARCH (2020)
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
Alexandre J. Debacker et al.
MOLECULAR THERAPY (2020)
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
Constantine E. Kosmas et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine
Domenico Lombardo et al.
JOURNAL OF NANOMATERIALS (2019)
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Piotr S. Kowalski et al.
MOLECULAR THERAPY (2019)
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Eliane Sardh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
Ghanbar Mahmoodi Chalbatani et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Clinical advances of siRNA therapeutics
Bo Hu et al.
JOURNAL OF GENE MEDICINE (2019)
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics
Jayesh A. Kulkarni et al.
ACCOUNTS OF CHEMICAL RESEARCH (2019)
Editorial focus: understanding off-target effects as the key to successful RNAi therapy
Rafal Bartoszewski et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2019)
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akin Akinc et al.
NATURE NANOTECHNOLOGY (2019)
Nanoparticles in the clinic: An update
Aaron C. Anselmo et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2019)
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
Advances in Biomaterials for Drug Delivery
Owen S. Fenton et al.
ADVANCED MATERIALS (2018)
A review on cationic lipids with different linkers for gene delivery
Defu Zhi et al.
ADVANCES IN COLLOID AND INTERFACE SCIENCE (2018)
Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
Jennifer L. S. Willoughby et al.
MOLECULAR THERAPY (2018)
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
Aaron D. Springer et al.
NUCLEIC ACID THERAPEUTICS (2018)
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
Yehuda Handelsman et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
The Multirole of Liposomes in Therapy and Prevention of infectious Diseases
Roberto Nisini et al.
FRONTIERS IN IMMUNOLOGY (2018)
Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages
Parisa Ghasemiyeh et al.
RESEARCH IN PHARMACEUTICAL SCIENCES (2018)
RNA interference-based therapy and its delivery systems
Xiuhui Chen et al.
CANCER AND METASTASIS REVIEWS (2018)
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Matthias A. Oberli et al.
NANO LETTERS (2017)
Efficient Targeting and Activation of Antigen Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Frank Liang et al.
MOLECULAR THERAPY (2017)
Lipid Nanoparticle Systems for Enabling Gene Therapies
Pieter R. Cullis et al.
MOLECULAR THERAPY (2017)
Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA
Siddharth Patel et al.
NANO LETTERS (2017)
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Norbert Pardi et al.
NATURE (2017)
Overcoming cellular barriers for RNA therapeutics
Steven F. Dowdy
NATURE BIOTECHNOLOGY (2017)
Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs
Anastasia Khvorova
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo
Xi Zhu et al.
THERANOSTICS (2017)
Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek et al.
GENOME MEDICINE (2017)
Tools for translation: non-viral materials for therapeutic mRNA delivery
Khalid A. Hajj et al.
NATURE REVIEWS MATERIALS (2017)
PCSK9 inhibitors: A new era of lipid lowering therapy
Rahul Chaudhary et al.
WORLD JOURNAL OF CARDIOLOGY (2017)
Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention
Dominik Witzigmann et al.
HEPATOLOGY RESEARCH (2016)
Liver fat accumulation is associated with circulating PCSK9
Massimiliano Ruscica et al.
ANNALS OF MEDICINE (2016)
Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes
Garth A. Kinberger et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance The GAUSS-3 Randomized Clinical Trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Sam Chen et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes
Thazha P. Prakash et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites
Peter Cimermancic et al.
JOURNAL OF MOLECULAR BIOLOGY (2016)
Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
Colton M. Miller et al.
NUCLEIC ACIDS RESEARCH (2016)
The delivery of therapeutic oligonucleotides
Rudolph L. Juliano
NUCLEIC ACIDS RESEARCH (2016)
Application of liposomes in medicine and drug delivery
Hadis Daraee et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2016)
Liposomes as nanomedical devices
Giuseppina Bozzuto et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Asialoglycoprotein receptor mediated hepatocyte targeting - Strategies and applications
Anisha A. D'Souza et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Advances and Challenges of Liposome Assisted Drug Delivery
Lisa Sercombe et al.
FRONTIERS IN PHARMACOLOGY (2015)
The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling
Renata Grozovsky et al.
NATURE MEDICINE (2015)
PCSK9 and lipid lowering drugs
Yuan-Lin Guo et al.
CLINICA CHIMICA ACTA (2014)
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
Eli M. Roth et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Liposomes in tissue engineering and regenerative medicine
Nelson Monteiro et al.
JOURNAL OF THE ROYAL SOCIETY INTERFACE (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody
Eli M. Roth et al.
FUTURE CARDIOLOGY (2014)
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
Michela Flego et al.
BMC MEDICINE (2013)
Delivery materials for siRNA therapeutics
Rosemary Kanasty et al.
NATURE MATERIALS (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Liposome: classification, preparation, and applications
Abolfazl Akbarzadeh et al.
NANOSCALE RESEARCH LETTERS (2013)
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
Barbara L. Mui et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: Lost and found
Eirini I. Rigopoulou et al.
AUTOIMMUNITY REVIEWS (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Rosemary L. Kanasty et al.
MOLECULAR THERAPY (2012)
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Nathan M. Belliveau et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity
Dirk Roggenbuck et al.
AUTOIMMUNITY HIGHLIGHTS (2012)
Current progress of siRNA/shRNA therapeutics in clinical trials
John C. Burnett et al.
BIOTECHNOLOGY JOURNAL (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Delivery of siRNA Therapeutics: Barriers and Carriers
Jie Wang et al.
AAPS JOURNAL (2010)
Long-Term Safety and Efficacy of Triple Combination Ezetimibe/Simvastatin Plus Extended-Release Niacin in Patients With Hyperlipidemia
Sergio Fazio et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Katrin Knop et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Rational design of cationic lipids for siRNA delivery
Sean C. Semple et al.
NATURE BIOTECHNOLOGY (2010)
Strategies in the design of nanoparticles for therapeutic applications
Robby A. Petros et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
siRNA delivery systems for cancer treatment
Yu-Kyoung Oh et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
RNAi-based therapeutics-current status, challenges and prospects
Katrin Tiemann et al.
EMBO MOLECULAR MEDICINE (2009)
Solid Lipid Nanoparticles: A Modern Formulation Approach in Drug Delivery System
S. Mukherjee et al.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver
Akin Akinc et al.
MOLECULAR THERAPY (2009)
Knocking down barriers: advances in siRNA delivery
Kathryn A. Whitehead et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Safety of niacin and simvastatin combination therapy
Harold Bays
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Frank Alexis et al.
MOLECULAR PHARMACEUTICS (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Encapsulation and release of a hydrophobic drug from hydroxyapatite coated liposomes
Qingguo Xu et al.
BIOMATERIALS (2007)
Opinion - How many drug targets are there?
John P. Overington et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Cubic phases in phosphatidylcholine-cholesterol mixtures: Cholesterol as membrane fusogen''
Boris G. Tenchov et al.
BIOPHYSICAL JOURNAL (2006)
Interrogating the druggable genome with structural informatics
Kevin Hambly et al.
MOLECULAR DIVERSITY (2006)
Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery
James Heyes et al.
JOURNAL OF CONTROLLED RELEASE (2006)
RNAi-mediated gene silencing in non-human primates
TS Zimmermann et al.
NATURE (2006)
Chemical modification of siRNAs to improve serum stability without loss of efficacy
S Choung et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review
William Insull
SOUTHERN MEDICAL JOURNAL (2006)
The druggable genome: an update
AP Russ et al.
DRUG DISCOVERY TODAY (2005)
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
J Heyes et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery
CN Landen et al.
CANCER RESEARCH (2005)
Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression
E Ambegia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2005)
siRNA therapeutics: Big potential from small RNAs
RCC Ryther et al.
GENE THERAPY (2005)
Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor
PCN Rensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis
S Matzno et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells
F Czauderna et al.
NUCLEIC ACIDS RESEARCH (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The druggable genome
AL Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes
EAL Biessen et al.
BIOCONJUGATE CHEMISTRY (2002)
Colesevelam hydrochloride: A novel bile acid-binding resin
MA Aldridge et al.
ANNALS OF PHARMACOTHERAPY (2001)
Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes
N Maurer et al.
BIOPHYSICAL JOURNAL (2001)
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures
SC Semple et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2001)
Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor
M Meier et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Share Paper
